Preliminary results suggest some efficacy of this combination in certain PV and MF patients, even those previously intolerant to IFNα therapy, with a decrease in JAK2V617F VAF and in fibrosis65,66. This evidence concerns the gene IFNA1 and acquired polycythemia vera.